Gerald Baty

Encysive Pharmaceuticals, Inc. discovers, develops and markets drugs for the treatment of cardiovascular, vascular and related inflammatory diseases. The firm focuses its research and development programs on the treatment and prevention of interrelated diseases of the vascular endothelium, inflammatory cascade and vascular diseases. The company was founded by James T. Willerson in 1989 and is headquartered in Houston, TX.

Novazyme Pharmaceuticals, Inc. researches and develops methods for modifying recombinantly produced enzymes. It develops a series of novel protein engineering technologies that have been shown in pre-clinical studies to greatly enhance the targeting and uptake of replacement enzymes. Novazyme's technologies also have application for developing advanced monoclonal antibodies and gene therapies. The company is located in Oklahoma City, OK.

Mt. Cook Pharma, Inc. provides treatment for urological diseases. It offers services to overactive bladder, lower urinary symptoms, and interstitial cystitis diseases. The company was headquartered in Princeton, NJ.

Transave, Inc. is a biopharmaceutical company focused on developing innovative, inhaled pharmaceuticals for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. They are committed to significantly improving the quality of life and healthcare of patients suffering from these life-threatening diseases. Its operating principles are centered on teamwork, openness, mutual respect, diversity of opinion, trust, accountability and innovative science. They are developing products based on Transave's proprietary liposomal technology designed specifically for lung delivery. Its focus is on reformulating off-patent, established drugs into unique liposomal technology - based inhaled pharmaceuticals for the localized, site-specific treatment of serious lung diseases. Transave's proprietary liposomal technology allows for the sustained release of a drug in the lung's microenvironment. By remaining in the lungs for a prolonged period and potentially minimizing systemic exposure, Transave's liposomal technology offers the potential for changing the product profile, improving delivery of the compound to the lung and enhancing the therapeutic index of established pharmaceuticals.

AxioMed Spine Corp. was formed in 2001 to develop products with a goal of restoring spinal function to patients with degenerative spine disease; thus advancing the standard of care beyond fusion and first generation artificial discs. Since its inception, AxioMed has secured over $34M in private equity financing from prestigious venture capitalists. The company´s Freedom Lumbar Disc has been developed and clinical trials initiated. The company is headed by CEO, Patrick McBrayer, who joined AxioMed in early 2006. Mr. McBrayer along with founder and COO, James Kuras, lead an experienced management and development team with significant history and expertise in spinal implants, including early artificial disc development efforts. Company employment includes professionals with extensive spine and engineering experience. The team is augmented by a Medical Advisory Panel of surgeons from leading spine centers and universities. The company´s headquarters include product development and testing, clinical and regulatory affairs, and manufacturing. AxioMed will leverage its background in lumbar disc replacement with an ongoing development project for the cervical spine.